The role of CD4+ T cells in tumor and chronic viral immune responses. 2023

Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
Institute of Hepatopancreatobiliary Surgery Chongqing General Hospital Chongqing China.

Immunotherapies are mainly aimed to promote a CD8+ T cell response rather than a CD4+ T cell response as cytotoxic T lymphocytes (CTLs) can directly kill target cells. Recently, CD4+ T cells have received more attention due to their diverse roles in tumors and chronic viral infections. In antitumor and antichronic viral responses, CD4+ T cells relay help signals through dendritic cells to indirectly regulate CD8+ T cell response, interact with B cells or macrophages to indirectly modulate humoral immunity or macrophage polarization, and inhibit tumor blood vessel formation. Additionally, CD4+ T cells can also exhibit direct cytotoxicity toward target cells. However, regulatory T cells exhibit immunosuppression and CD4+ T cells become exhausted, which promote tumor progression and chronic viral persistence. Finally, we also outline immunotherapies based on CD4+ T cells, including adoptive cell transfer, vaccines, and immune checkpoint blockade. Overall, this review summarizes diverse roles of CD4+ T cells in the antitumor or protumor and chronic viral responses, and also highlights the immunotherapies based on CD4+ T cells, giving a better understanding of their roles in tumors and chronic viral infections.

UI MeSH Term Description Entries

Related Publications

Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
March 1999, The Journal of experimental medicine,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
April 2008, Immunological reviews,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
January 2013, Frontiers in immunology,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
January 2020, Computational and mathematical methods in medicine,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
January 2003, Novartis Foundation symposium,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
July 2012, The Journal of experimental medicine,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
August 1991, Current opinion in immunology,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
March 2007, Journal of immunology (Baltimore, Md. : 1950),
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
July 2003, Journal of immunological methods,
Luoyingzi Xie, and Jingyi Fang, and Juncheng Yu, and Weinan Zhang, and Zhiqiang He, and Lilin Ye, and Huaizhi Wang
January 2023, Frontiers in immunology,
Copied contents to your clipboard!